| DB ID | MyCo_5930 |
| Title | Up-regulation of chemokine CXCL13 in systemic candidiasis |
| Year | 2017 |
| PMID | 29198822 |
| Fungal Diseases involved | Candidemia |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | albicans |
| Organism | Candida albicans |
| Ethical Statement | The study was approved by the Clinical Research Ethics Committee of our hospital according to guidelines for the protection of every subject. A written informed consent document was obtained from all participants before inclusion into this study. |
| Site of Infection | Bloodstream |
| Opportunistic invasive | Opportunistic |
| Sample type | Biopsy |
| Sample source | Extracted RNA |
| Host Group | Animal |
| Host Common name | Mice |
| Host Scientific name | Mus musculus |
| Biomarker Name | Chemokine CXCL13 |
| Biomarker Full Name | C-X-C motif chemokine ligand 15 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | China |
| Cohort | 114 patients with bloodstream infections as the experimental group, were finally recruited from the First Affiliated Hospital of Chongqing Medical University during November 2015 to April 2017. 112 patients were diagnosed based on a compatible clinical picture and positive blood culture results, and the identifications were performed using the VITEK 2 AST and YST commercial test kits at Clinical Microbiology Laboratory. Moreover, these 112 patients with bloodstream infections included 56 subjects with candida spp (26 C. albicans and 30 C. non-albicans) as candidemia group, and 56 patients with bacteria infections during the same period as bacteremia group. To march for age and gender, 36 patients without detectable pathogen infections were randomly selected as control group from the same hospital. All patients in this study with cancers, autoimmune diseases, neuro-inflammatory conditions and other serious infection diseases were excluded. The study was approved by the Clinical Research Ethics Committee of our hospital according to guidelines for the protection of every subject. A written informed consent document was obtained from all participants before inclusion into this study. |
| Cohort No. | 148 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Candida species are major causes of nosocomial bloodstream infections (BSIs), particularly among patients with long-term stays in intensive care units (ICU), immunosuppressive therapy, invasive devices use, and recent surgery. Invasive candidiasis (IC) has emerged as a life-threatening disease, causing substantial morbidity, mortality, and high healthcare cost. It was currently reported that candidemia was the third or fourth most common cause of healthcare associated BSIs in the USA, and hospitalization cost was believed to exceed 2 billion dollars per year. In recent years, despiting clinical practice guideline and new antifungal agents have advanced for the management of candidiasis, it still shows a high mortality, in part because of poor diagnostic sensitivity, drug resistance and high cost. C. albicans was the most frequent fungal species isolated from blood, followed by C. parapsilosis and C. glabrata. Early rapid diagnosis of candidemia is one of the most important elements of appropriate and efficient antifungal treatment. |
| Technique | PCR |
| Analysis Method | RT‑qPCR |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | ELISA, qRT-PCR |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
